Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed a Form 8-K reporting an event occurring on April 25, 2022. The filing concerns a board appointment and related director compensation, not operating or financial results.
Key Financial and Other Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes
- Frank Karbe was appointed to the board as a Class II director, effective April 25, 2022, with an initial term expiring at the 2024 annual meeting of stockholders.
- Mr. Karbe was appointed to the audit and compensation committees.
- The board determined that Mr. Karbe satisfies applicable Nasdaq independence requirements.
Compensation, Outlook, and Risks
- Mr. Karbe received an option to purchase 20,000 shares of common stock under the company’s Non-Employee Director Compensation Program.
- The option has a 10-year term and vests and becomes exercisable over three years, subject to continued board service.
- He will receive cash compensation under the same director compensation program and enter into the company’s standard director indemnification agreement.
- The filing states there were no arrangements or understandings with other persons regarding his selection and no related-person transactions with the company.
- The filing provides no guidance, business outlook, contingencies, or unusual financial items.
Investor Verification Items
- Verify the terms, exercise price, and accounting treatment of the 20,000-share option, which are not stated in the filing text.
- Review the company’s director compensation program for the applicable cash compensation and other benefits.
- Confirm Mr. Karbe’s committee assignments and board term at subsequent proxy or corporate governance disclosures.